The short answer is that the oncogenic proteins are "addicted" to HSP90 which is required for proper folding/configuration. Inhibition of HSP90 results in degradation of the oncoprotein.
Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.